ADH-503 NEW
| Price | $48 | $77 | $129 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: ADH-503 | CAS No.: 2055362-74-6 |
| Purity: 98.28% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | ADH-503 |
| Description | ADH-503 (GB1275) is an orally available, allosteric CD11b small molecule agonist that can lead to repolarization of tumor-associated macrophages, reduction in the number of tumor-infiltrating immunosuppressive myeloid cells, and enhancement of dendritic cell responses. |
| Animal Research | Animal Model:Male rats.Dosage:30,100 mg/kg (Pharmacokinetic Analysis). Administration:Oral gavage twice a day; on days 1 and 5 |
| In vitro | METHODS: ADH-503 (GB1275) (4 μM, 10 days) was used to investigate the expression of macrophage markers in two syngeneic orthotopic models. RESULTS After treatment with ADH-503 (GB1275), macrophages expressed higher levels of MHCI, MHCII, CD80, and CD86, indicating improved antigen presentation properties of the remaining macrophages. [1] |
| In vivo | METHODS: ADH-503 (GB1275) (30, 100 mg/kg, oral) was administered to rats and C57/B6 mice to test the pharmacokinetics (PK) and safety. RESULTS The mean half-life of ADH-503 (GB1275) in rats and mice after administration was 4.68 and 3.95 hours, and the Cmax and AUC0-t in plasma were 1716 and 2594 ng/mL and 6950 and 13962 ng.h/mL, respectively. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 5.25 mg/mL (10 mM) |
| Keywords | tumor-infiltrating | ADH-503 | ADH 503 | CD11b | GB 1275 | Inhibitor | tumorassociated | dendritic | immunosuppressive | ADH503 | macrophages | repolarization | allosteric | inhibit | Complement System | orally | GB-1275 |
| Inhibitors Related | EG01377 2HCl | Iptacopan hydrochloride | SB290157 trifluoroacetate | LEP(116-130)(mouse)TFA(258276-95-8 free base) | BCX 1470 hydrochloride | Complement C5-IN-1 | CP-289 | Dexamethasone | CP-447697 | Complement factor D-IN-2 | Cyclosporin A | 3-Phenoxybenzaldehyde |
| Related Compound Libraries | Bioactive Compound Library | Orally Active Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1mg |
VIP1Y
|
Hubei Chuchang Biotech Co., Ltd.
|
2024-03-28 | |
| $117.00/2mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-11 | |
| $28.50/10mg |
Hubei Xindesheng Material Technology Co., Ltd.
|
2020-11-04 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY